pharma-skepticism

ALTAIR Missed Its Primary Endpoint. The Press Tour Found Something Else.

A phase 3 trial testing chemotherapy in ctDNA-positive colorectal cancer patients missed its primary endpoint at p=0.107, and a post-hoc reanalysis is doing the public-facing work.